key: cord-0049077-s3gkep8h
authors: (Jiro Kamiyama), 神山 治郎; (Koichi Yasaka), 八坂 剛一; (Saki Sakamoto), 坂本 早紀; (Katsura Hayakawa), 早川 桂; (Yuko Egawa), 江川 裕子; (Shigemasa Taguchi), 田口 茂正; (Kazuya Kiyota), 清田 和也
title: ECMO管理を要した重症COVID–19市中肺炎に対して腹臥位療法やステロイドの全身投与により軽快した2例(Two cases of severe coronavirus disease 2019 community–acquired pneumonia successfully treated with extracorporeal membrane oxygenation and prone positioning and systemic corticosteroid therapy)
date: 2020-08-06
journal: nan
DOI: 10.1002/jja2.12488
sha: 8ab1765c6c671b13f8b356a821eaae72df7df69c
doc_id: 49077
cord_uid: s3gkep8h

The first case was that of a 58–year–old man diagnosed with coronavirus disease 2019 (COVID–19) pneumonia after 7 days of fever. Favipiravir was administered on admission; however, the patient’s respiratory status worsened with high fever. On day 2 of admission, after tracheal intubation, maintaining oxygenation was difficult after initiating mechanical ventilation, and extracorporeal membrane oxygenation (ECMO) was initiated. On day 5, prone positioning and corticosteroid therapy were started. The patient was weaned from ECMO on day 9 and from ventilator support on day 11. On day 27, he was discharged ambulatory. The second case was that of a 44–year–old man who complained of dyspnea after 12 days of fever. After tracheal intubation, he was diagnosed with COVID–19 pneumonia. Favipiravir was administered on admission; nevertheless, the patient’s respiratory status worsened gradually with high fever. On day 4 of admission, ECMO and corticosteroid therapy were initiated. On day 5, prone positioning was started. The patient was weaned from ECMO on day 12 and from ventilator support on day 15. On day 30, he was discharged ambulatory. The aggravation of COVID–19 pneumonia may be associated with excessive inflammation; therefore, some patients were effectively treated with corticosteroid therapy.

The first case was that of a 58-year-old man diagnosed with coronavirus disease 2019 (COVID-19) pneumonia after 7 days of fever. Favipiravir was administered on admission; however, the patient's respiratory status worsened with high fever. On day 2 of admission, after tracheal intubation, maintaining oxygenation was difficult after initiating mechanical ventilation, and extracorporeal membrane oxygenation (ECMO) was initiated. On day 5, prone positioning and corticosteroid therapy were started. The patient was weaned from ECMO on day 9 and from ventilator support on day 11. On day 27, he was discharged ambulatory. The second case was that of a 44-year-old man who complained of dyspnea after 12 days of fever. After tracheal intubation, he was diagnosed with COVID-19 pneumonia. Favipiravir was administered on admission; nevertheless, the patient's respiratory status worsened gradually with high fever. On day 4 of admission, ECMO and corticosteroid therapy were initiated. On day 5, prone positioning was started. The patient was weaned from ECMO on day 12 and from ventilator support on day 15. On day 30, he was discharged ambulatory. The aggravation of COVID-19 pneumonia may be associated with excessive inflammation; therefore, some patients were effectively treated with corticosteroid therapy. 

Clinical characteristics of coronavirus disease 2019 in China

Ventilator-induced lung injury

Fifty Years of Research in ARDS. Spontaneous Breathing during Mechanical Ventilation. Risks, Mechanisms, and Management

Effects of prone positioning on lung protection in patients with acute respiratory distress syndrome

Prone positioning in severe acute respiratory distress syndrome

COVID-19: consider cytokine storm syndromes and immunosuppression

WHO: Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected

clinical-management-of-severe-acute-respiratory-infectionwhen-novel-coronavirus-(ncov)-infection-is-suspected

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Temporal dynamics in viral shedding and transmissibility of COVID-19

ICU-acquired weakness and recovery from critical illness

Why tocilizumab could be an effective treatment for severe COVID-19?